Edition:
India

Fresenius SE & Co KGaA (FREG.DE)

FREG.DE on Xetra

67.30EUR
23 May 2018
Change (% chg)

€-1.20 (-1.75%)
Prev Close
€68.50
Open
€68.12
Day's High
€68.48
Day's Low
€66.72
Volume
1,196,284
Avg. Vol
1,505,918
52-wk High
€80.07
52-wk Low
€58.96

Select another date:

Fri, May 18 2018

Photo

Fresenius CEO defends canceled Akorn deal

FRANKFURT/BERLIN Fresenius SE's chief executive has defended the company's decision to pull out of a planned $4.8 billion takeover of Akorn , saying it was the only option after uncovering data integrity breaches at the U.S drugmaker.

UPDATE 1-Fresenius CEO defends cancelled Akorn deal

* Expects legal proceedings to conclude in 2019 (Adds details on expenses, comment on provision, analyst)

Fresenius CEO defends cancelled Akorn deal

FRANKFURT/BERLIN, May 18 Fresenius SE's chief executive has defended the company's decision to pull out of a planned $4.8 billion takeover of Akorn, saying it was the only option after uncovering data integrity breaches at the U.S drugmaker.

Fresenius Q1 net income slips 2 pct on strong euro

BERLIN, May 3 German healthcare group Fresenius SE posted a slight decline in quarterly profit on Thursday, hurt by a strong euro, and confirmed its full-year guidance.

Fresenius alleges 'blatant fraud' at U.S. drugmaker Akorn

WILMINGTON, Del./NEW YORK German healthcare group Fresenius alleged it uncovered "blatant fraud at the very top level" of U.S. generic drugmaker Akorn Inc after Fresenius agreed to acquire the company for $4.75 billion, according to a court filing made public late on Tuesday.

UPDATE 2-Fresenius alleges 'blatant fraud' at U.S. drugmaker Akorn

WILMINGTON, Del./NEW YORK, May 2 German healthcare group Fresenius alleged it uncovered "blatant fraud at the very top level" of U.S. generic drugmaker Akorn Inc after Fresenius agreed to acquire the company for $4.75 billion, according to a court filing made public late on Tuesday.

Fresenius alleges "blatant fraud" at abandoned target Akorn

WILMINGTON, Del., May 2 German healthcare group Fresenius alleged it uncovered "blatant fraud at the very top level" of U.S. generic drugmaker Akorn Inc after Fresenius agreed to acquire the company for $4.75 billion, according to a filing in Delaware's Court of Chancery.

BRIEF-Fresenius says believes that Akorn lawsuit is without foundation

* AKORN, INC. SUES FRESENIUS FOR CONSUMMATION OF MERGER AGREEMENT AFTER ITS TERMINATION BY FRESENIUS

Jilted Akorn sues Fresenius over deal termination

FRANKFURT U.S. generic drugmaker Akorn is taking former suitor Fresenius to court after the German healthcare group canceled their $4.75 billion takeover agreement.

Fresenius shares gain after it ditches Akorn takeover

FRANKFURT, April 23 Shares in healthcare group Fresenius jumped as much as 3.9 percent after it pulled out of the $4.75 billion acquisition of Akorn, with analysts saying it was extricating itself from taking on an underperforming business.

Select another date: